Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of GW815SF in COPD
NCT00269087Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2005
- Primary completion
- Oct 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, single-arm trial of fluticasone propionate and salmeterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Primary endpoint: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs). Started Jan 2005; status: completed.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00269087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269087.